January 18, 2007 -- Adherex Technologies purchased options held by GlaxoSmithKline on eniluracil, a cancer compound that failed a Phase III trial; DynPort Vaccine and Baxter Healthcare began a Phase I trial of a treatment for nerve agent exposure; GlaxoSmithKline began a head-to-head test of Cervarix against Gardasil from Merck; Barrier Therapeutics reported positive results for a Phase II trial of anti-itching drug Hivenyl; MGI Pharma published old data from a trial of Saforis Powder for oral mucositis; and Alexza Pharma completed enrollment in a Phase IIa trial of a Staccato version of an anti-psychotic. The Centient Biotech 200™ dropped 12 points to 4088, a loss of .31%. More details...
